<s id="wsj_1956.1"> 27
3 	 0 	 N/N 	 1 	 Corp. National
3 	 1 	 N/N 	 1 	 Corp. Patent
3 	 2 	 N/N 	 1 	 Corp. Development
3 	 4 	 (S[dcl]\NP)/S[dcl] 	 1 	 Corp. said
5 	 6 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 it plans
5 	 8 	 (S[b]\NP)/NP 	 1 	 it purchase <XB>
6 	 4 	 (S[dcl]\NP)/S[dcl] 	 2 	 plans said
7 	 6 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to plans
8 	 7 	 (S[to]\NP)/(S[b]\NP) 	 2 	 purchase to
8 	 22 	 ((S\NP)\(S\NP))/NP 	 2 	 purchase in
9 	 8 	 (S[b]\NP)/NP 	 2 	 as purchase
9 	 15 	 (NP\NP)/NP 	 1 	 as of
10 	 9 	 ((NP[nb]/N)/PP)/(S[adj]\NP) 	 3 	 many as
11 	 9 	 ((NP[nb]/N)/PP)/(S[adj]\NP) 	 2 	 as as
12 	 11 	 PP/NP 	 1 	 200,000 as
14 	 9 	 ((NP[nb]/N)/PP)/(S[adj]\NP) 	 1 	 shares as
14 	 13 	 N/N 	 1 	 shares common
21 	 15 	 (NP\NP)/NP 	 2 	 unit of
21 	 16 	 NP[nb]/N 	 1 	 unit its
21 	 17 	 N/N 	 1 	 unit 81%-controlled
21 	 18 	 N/N 	 1 	 unit Interferon
21 	 19 	 N/N 	 1 	 unit Sciences
21 	 20 	 N/N 	 1 	 unit Inc.
26 	 22 	 ((S\NP)\(S\NP))/NP 	 3 	 purchases in
26 	 23 	 N/N 	 1 	 purchases periodic
26 	 25 	 N/N 	 1 	 purchases open-market
<\s>
<s id="wsj_1956.2"> 19
2 	 0 	 NP[nb]/N 	 1 	 shares The
2 	 1 	 N/N 	 1 	 shares 200,000
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 shares are
3 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 are excluding
5 	 4 	 (N/N)/(N/N) 	 2 	 23 about
6 	 3 	 (S[dcl]\NP)/NP 	 2 	 % are
6 	 5 	 N/N 	 1 	 % 23
6 	 7 	 (NP\NP)/NP 	 1 	 % of
8 	 9 	 (NP[nb]/N)\NP 	 2 	 Interferon 's
11 	 7 	 (NP\NP)/NP 	 2 	 shares of
11 	 9 	 (NP[nb]/N)\NP 	 1 	 shares 's
11 	 10 	 N/N 	 1 	 shares common
11 	 12 	 S[adj]\NP 	 1 	 shares outstanding <XB>
16 	 15 	 N/N 	 1 	 Patent National
16 	 17 	 (NP[nb]/N)\NP 	 2 	 Patent 's
18 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 stake excluding
18 	 17 	 (NP[nb]/N)\NP 	 1 	 stake 's
<\s>
<s id="wsj_1956.3"> 25
7 	 0 	 (S[ng]\NP)/NP 	 2 	 approval Noting
7 	 1 	 NP[nb]/N 	 1 	 approval the
7 	 2 	 N/N 	 1 	 approval recent
7 	 3 	 N/N 	 1 	 approval Food
7 	 5 	 N/N 	 1 	 approval Drug
7 	 6 	 N/N 	 1 	 approval Administration
7 	 8 	 (NP\NP)/NP 	 1 	 approval of
9 	 10 	 (NP[nb]/N)\NP 	 2 	 Interferon 's
13 	 8 	 (NP\NP)/NP 	 2 	 treatment of
13 	 10 	 (NP[nb]/N)\NP 	 1 	 treatment 's
13 	 11 	 N/N 	 1 	 treatment genital
13 	 12 	 N/N 	 1 	 treatment warts
16 	 15 	 N/N 	 1 	 Patent National
16 	 17 	 (S[dcl]\NP)/S[dcl] 	 1 	 Patent said
18 	 19 	 (S[dcl]\NP)/S[dcl] 	 1 	 it believes
19 	 17 	 (S[dcl]\NP)/S[dcl] 	 2 	 believes said
20 	 21 	 (NP[nb]/N)\NP 	 2 	 Interferon 's
22 	 21 	 (NP[nb]/N)\NP 	 1 	 stock 's
22 	 23 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 stock is
22 	 24 	 S[adj]\NP 	 1 	 stock undervalued <XB>
23 	 19 	 (S[dcl]\NP)/S[dcl] 	 2 	 is believes
24 	 23 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 undervalued is
<\s>
